• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Benzinga's Top Ratings Upgrades, Downgrades For May 1, 2023

    5/1/23 11:00:42 AM ET
    $ALHC
    $ARBK
    $ARCB
    $AVB
    Medical Specialities
    Health Care
    Finance: Consumer Services
    Finance
    Get the next $ALHC alert in real time by email

    Upgrades

    Telsey Advisory Group upgraded the previous rating for Allbirds Inc (NASDAQ:BIRD) from Market Perform to Outperform. Allbirds earned $0.17 in the fourth quarter, compared to $0.09 in the year-ago quarter. The current stock performance of Allbirds shows a 52-week-high of $6.12 and a 52-week-low of $1.03. Moreover, at the end of the last trading period, the closing price was at $1.25.

    For Stoke Therapeutics Inc (NASDAQ:STOK), B of A Securities upgraded the previous rating of Underperform to Neutral. Stoke Therapeutics earned $0.65 in the fourth quarter, compared to $0.66 in the year-ago quarter. The current stock performance of Stoke Therapeutics shows a 52-week-high of $22.78 and a 52-week-low of $6.88. Moreover, at the end of the last trading period, the closing price was at $8.89.

    According to Northland Capital Markets, the prior rating for Power Integrations Inc (NASDAQ:POWI) was changed from Market Perform to Outperform. Power Integrations earned $0.48 in the fourth quarter, compared to $0.83 in the year-ago quarter. At the moment, the stock has a 52-week-high of $91.98 and a 52-week-low of $59.30. Power Integrations closed at $72.78 at the end of the last trading period.

    For Zillow Group Inc (NASDAQ:ZG), Bernstein upgraded the previous rating of Underperform to Market Perform. In the fourth quarter, Zillow Gr showed an EPS of $0.21, compared to $0.42 from the year-ago quarter. At the moment, the stock has a 52-week-high of $48.48 and a 52-week-low of $26.24. Zillow Gr closed at $42.78 at the end of the last trading period.

    According to Raymond James, the prior rating for Carter Bankshares Inc (NASDAQ:CARE) was changed from Market Perform to Outperform. Carter Bankshares earned $0.68 in the first quarter, compared to $0.36 in the year-ago quarter. At the moment, the stock has a 52-week-high of $18.84 and a 52-week-low of $12.61. Carter Bankshares closed at $12.85 at the end of the last trading period.

    Guggenheim upgraded the previous rating for Biogen Inc (NASDAQ:BIIB) from Neutral to Buy. For the first quarter, Biogen had an EPS of $3.40, compared to year-ago quarter EPS of $3.62. The current stock performance of Biogen shows a 52-week-high of $311.79 and a 52-week-low of $187.22. Moreover, at the end of the last trading period, the closing price was at $304.23.

    B of A Securities upgraded the previous rating for Comcast Corp (NASDAQ:CMCSA) from Neutral to Buy. For the first quarter, Comcast had an EPS of $0.92, compared to year-ago quarter EPS of $0.86. At the moment, the stock has a 52-week-high of $44.62 and a 52-week-low of $28.39. Comcast closed at $41.37 at the end of the last trading period.

    For General Motors Co (NYSE:GM), Morgan Stanley upgraded the previous rating of Equal-Weight to Overweight. General Motors earned $2.21 in the first quarter, compared to $2.09 in the year-ago quarter. At the moment, the stock has a 52-week-high of $43.63 and a 52-week-low of $30.34. General Motors closed at $33.04 at the end of the last trading period.

    According to HC Wainwright & Co., the prior rating for Argo Blockchain PLC (NASDAQ:ARBK) was changed from Neutral to Buy.

    For Iamgold Corp (NYSE:IAG), BMO Capital upgraded the previous rating of Market Perform to Outperform. For the fourth quarter, Iamgold had an EPS of $0.02, compared to year-ago quarter EPS of $0.09. At the moment, the stock has a 52-week-high of $3.23 and a 52-week-low of $0.92. Iamgold closed at $2.85 at the end of the last trading period.

    For Otis Worldwide Corp (NYSE:OTIS), Wells Fargo upgraded the previous rating of Underweight to Equal-Weight. For the first quarter, Otis Worldwide had an EPS of $0.80, compared to year-ago quarter EPS of $0.77. At the moment, the stock has a 52-week-high of $87.33 and a 52-week-low of $62.56. Otis Worldwide closed at $85.30 at the end of the last trading period.

    Wells Fargo upgraded the previous rating for Manitowoc Co Inc (NYSE:MTW) from Underweight to Equal-Weight. For the fourth quarter, Manitowoc Co had an EPS of $0.74, compared to year-ago quarter EPS of $0.27. At the moment, the stock has a 52-week-high of $20.20 and a 52-week-low of $7.55. Manitowoc Co closed at $15.29 at the end of the last trading period.

    For Alignment Healthcare Inc (NASDAQ:ALHC), Raymond James upgraded the previous rating of Market Perform to Outperform. For the fourth quarter, Alignment Healthcare had an EPS of $0.31, compared to year-ago quarter EPS of $0.27. The stock has a 52-week-high of $19.13 and a 52-week-low of $4.88. At the end of the last trading period, Alignment Healthcare closed at $6.29.

    For Logitech International SA (NASDAQ:LOGI), Morgan Stanley upgraded the previous rating of Underweight to Equal-Weight. At the moment, the stock has a 52-week-high of $68.17 and a 52-week-low of $41.82. Logitech International closed at $59.46 at the end of the last trading period.

    For Teradata Corp (NYSE:TDC), Guggenheim upgraded the previous rating of Neutral to Buy. Teradata earned $0.35 in the fourth quarter, compared to $0.57 in the year-ago quarter. The stock has a 52-week-high of $42.79 and a 52-week-low of $28.74. At the end of the last trading period, Teradata closed at $38.71.

    Stifel upgraded the previous rating for The Scotts Miracle Gro Co (NYSE:SMG) from Hold to Buy. For the first quarter, Scotts Miracle Gro had an EPS of $1.02, compared to year-ago quarter EPS of $0.88. At the moment, the stock has a 52-week-high of $118.03 and a 52-week-low of $39.06. Scotts Miracle Gro closed at $66.81 at the end of the last trading period.

    For Essex Property Trust Inc (NYSE:ESS), Piper Sandler upgraded the previous rating of Neutral to Overweight. Essex Property Trust earned $3.65 in the first quarter, compared to $3.37 in the year-ago quarter. The current stock performance of Essex Property Trust shows a 52-week-high of $345.89 and a 52-week-low of $195.03. Moreover, at the end of the last trading period, the closing price was at $219.73.

    According to Piper Sandler, the prior rating for AvalonBay Communities Inc (NYSE:AVB) was changed from Underweight to Neutral. In the first quarter, AvalonBay Communities showed an EPS of $2.57, compared to $2.26 from the year-ago quarter. At the moment, the stock has a 52-week-high of $241.68 and a 52-week-low of $153.07. AvalonBay Communities closed at $180.37 at the end of the last trading period.

    See all analyst ratings upgrades.

    Downgrades

    OTR Global downgraded the previous rating for Guardant Health Inc (NASDAQ:GH) from Mixed to Negative. Guardant Health earned $1.17 in the fourth quarter, compared to $0.69 in the year-ago quarter. The stock has a 52-week-high of $65.82 and a 52-week-low of $20.67. At the end of the last trading period, Guardant Health closed at $22.56.

    For TAL Education Group (NYSE:TAL), UBS downgraded the previous rating of Buy to Neutral. TAL Education earned $0.02 in the fourth quarter, compared to $0.17 in the year-ago quarter. The stock has a 52-week-high of $10.45 and a 52-week-low of $2.82. At the end of the last trading period, TAL Education closed at $5.86.

    Brookline Capital downgraded the previous rating for NightHawk Biosciences Inc (AMEX:NHWK) from Buy to Hold. In the fourth quarter, NightHawk Biosciences showed an EPS of $0.48, compared to $0.54 from the year-ago quarter. The current stock performance of NightHawk Biosciences shows a 52-week-high of $3.42 and a 52-week-low of $0.65. Moreover, at the end of the last trading period, the closing price was at $0.66.

    Northcoast Research downgraded the previous rating for Copart Inc (NASDAQ:CPRT) from Buy to Neutral. For the second quarter, Copart had an EPS of $0.61, compared to year-ago quarter EPS of $0.55. The current stock performance of Copart shows a 52-week-high of $79.09 and a 52-week-low of $51.11. Moreover, at the end of the last trading period, the closing price was at $79.05.

    Wedbush downgraded the previous rating for IVERIC bio Inc (NASDAQ:ISEE) from Outperform to Neutral. In the fourth quarter, IVERIC bio showed an EPS of $0.47, compared to $0.29 from the year-ago quarter. At the moment, the stock has a 52-week-high of $32.96 and a 52-week-low of $8.88. IVERIC bio closed at $32.89 at the end of the last trading period.

    Maxim Group downgraded the previous rating for Siyata Mobile Inc (NASDAQ:SYTA) from Buy to Hold. In the third quarter, Siyata Mobile showed an EPS of $0.03, compared to $0.99 from the year-ago quarter. The current stock performance of Siyata Mobile shows a 52-week-high of $1.62 and a 52-week-low of $0.10. Moreover, at the end of the last trading period, the closing price was at $0.11.

    For Shoe Carnival Inc (NASDAQ:SCVL), Williams Trading downgraded the previous rating of Buy to Hold. Shoe Carnival earned $0.79 in the fourth quarter, compared to $0.83 in the year-ago quarter. At the moment, the stock has a 52-week-high of $32.24 and a 52-week-low of $19.44. Shoe Carnival closed at $23.25 at the end of the last trading period.

    According to Raymond James, the prior rating for Valley National Bancorp (NASDAQ:VLY) was changed from Strong Buy to Market Perform. Valley Ntl earned $0.30 in the first quarter, compared to $0.28 in the year-ago quarter. At the moment, the stock has a 52-week-high of $13.06 and a 52-week-low of $7.91. Valley Ntl closed at $9.38 at the end of the last trading period.

    According to Janney Montgomery Scott, the prior rating for South Atlantic Bancshares Inc (OTC:SABK) was changed from Buy to Neutral.

    For IVERIC bio Inc (NASDAQ:ISEE), Guggenheim downgraded the previous rating of Buy to Neutral. IVERIC bio earned $0.47 in the fourth quarter, compared to $0.29 in the year-ago quarter. The stock has a 52-week-high of $32.96 and a 52-week-low of $8.88. At the end of the last trading period, IVERIC bio closed at $32.89.

    For ArcBest Corp (NASDAQ:ARCB), B of A Securities downgraded the previous rating of Neutral to Underperform. For the first quarter, ArcBest had an EPS of $1.58, compared to year-ago quarter EPS of $3.08. The stock has a 52-week-high of $104.87 and a 52-week-low of $65.93. At the end of the last trading period, ArcBest closed at $94.40.

    For Principal Financial Group Inc (NASDAQ:PFG), B of A Securities downgraded the previous rating of Buy to Neutral. In the first quarter, Principal Finl Gr showed an EPS of $1.48, compared to $1.51 from the year-ago quarter. The stock has a 52-week-high of $96.12 and a 52-week-low of $61.06. At the end of the last trading period, Principal Finl Gr closed at $74.69.

    Wells Fargo downgraded the previous rating for Doximity Inc (NYSE:DOCS) from Overweight to Equal-Weight. Doximity earned $0.22 in the third quarter, compared to $0.29 in the year-ago quarter. The current stock performance of Doximity shows a 52-week-high of $47.40 and a 52-week-low of $22.92. Moreover, at the end of the last trading period, the closing price was at $36.75.

    For Exxon Mobil Corp (NYSE:XOM), Goldman Sachs downgraded the previous rating of Buy to Neutral. In the first quarter, Exxon Mobil showed an EPS of $2.83, compared to $2.07 from the year-ago quarter. The current stock performance of Exxon Mobil shows a 52-week-high of $119.92 and a 52-week-low of $80.69. Moreover, at the end of the last trading period, the closing price was at $118.34.

    According to JonesTrading, the prior rating for Hanmi Financial Corp (NASDAQ:HAFC) was changed from Buy to Hold. For the first quarter, Hanmi Financial had an EPS of $0.72, compared to year-ago quarter EPS of $0.68. The current stock performance of Hanmi Financial shows a 52-week-high of $27.30 and a 52-week-low of $15.80. Moreover, at the end of the last trading period, the closing price was at $16.16.

    See all analyst ratings downgrades.

    Initiations

    ThinkEquity initiated coverage on Reunion Neuroscience Inc (NASDAQ:REUN) with a Buy rating. The price target for Reunion Neuroscience is set to $5.00. In the third quarter, Reunion Neuroscience showed an EPS of $0.43, compared to $0.51 from the year-ago quarter. The current stock performance of Reunion Neuroscience shows a 52-week-high of $7.62 and a 52-week-low of $0.63. Moreover, at the end of the last trading period, the closing price was at $0.81.

    Northland Capital Markets initiated coverage on NEXTracker Inc (NASDAQ:NXT) with a Market Perform rating. The price target for NEXTracker is set to $32.00. The stock has a 52-week-high of $37.83 and a 52-week-low of $28.24. At the end of the last trading period, NEXTracker closed at $31.49.

    With a Buy rating, Truist Securities initiated coverage on Edgewise Therapeutics Inc (NASDAQ:EWTX). The price target seems to have been set at $25.00 for Edgewise Therapeutics. Edgewise Therapeutics earned $0.31 in the fourth quarter, compared to $0.26 in the year-ago quarter. At the moment, the stock has a 52-week-high of $14.33 and a 52-week-low of $5.41. Edgewise Therapeutics closed at $8.77 at the end of the last trading period.

    With a Buy rating, Truist Securities initiated coverage on Coherus BioSciences Inc (NASDAQ:CHRS). The price target seems to have been set at $24.00 for Coherus BioSciences. In the fourth quarter, Coherus BioSciences showed an EPS of $0.60, compared to $0.46 from the year-ago quarter. The stock has a 52-week-high of $14.03 and a 52-week-low of $5.59. At the end of the last trading period, Coherus BioSciences closed at $7.23.

    With a Buy rating, Truist Securities initiated coverage on Treace Medical Concepts Inc (NASDAQ:TMCI). The price target seems to have been set at $33.00 for Treace Medical Concepts. Treace Medical Concepts earned $0.08 in the fourth quarter, compared to $0.12 in the year-ago quarter. The current stock performance of Treace Medical Concepts shows a 52-week-high of $27.97 and a 52-week-low of $12.49. Moreover, at the end of the last trading period, the closing price was at $24.49.

    With a Buy rating, Guggenheim initiated coverage on Endeavor Group Holdings Inc (NYSE:EDR). The price target seems to have been set at $33.00 for Endeavor Gr Hldgs. For the fourth quarter, Endeavor Gr Hldgs had an EPS of $0.72, compared to year-ago quarter EPS of $0.34. The stock has a 52-week-high of $26.26 and a 52-week-low of $17.43. At the end of the last trading period, Endeavor Gr Hldgs closed at $25.78.

    Guggenheim initiated coverage on MoonLake Immunotherapeutics (NASDAQ:MLTX) with a Buy rating. The price target for MoonLake is set to $51.00. For the fourth quarter, MoonLake had an EPS of $0.31, compared to year-ago quarter EPS of $0.27. At the moment, the stock has a 52-week-high of $26.24 and a 52-week-low of $4.37. MoonLake closed at $21.30 at the end of the last trading period.

    With an Outperform rating, SVB Leerink initiated coverage on Danaher Corp (NYSE:DHR). The price target seems to have been set at $300.00 for Danaher. Danaher earned $2.36 in the first quarter, compared to $2.76 in the year-ago quarter. The stock has a 52-week-high of $303.81 and a 52-week-low of $227.00. At the end of the last trading period, Danaher closed at $236.91.

    With a Buy rating, B of A Securities initiated coverage on Immunovant Inc (NASDAQ:IMVT). The price target seems to have been set at $26.00 for Immunovant. For the third quarter, Immunovant had an EPS of $0.49, compared to year-ago quarter EPS of $0.36. The stock has a 52-week-high of $20.24 and a 52-week-low of $3.15. At the end of the last trading period, Immunovant closed at $16.14.

    With a Buy rating, HC Wainwright & Co. initiated coverage on Invivyd Inc (NASDAQ:IVVD). The price target seems to have been set at $5.00 for Invivyd. Invivyd earned $0.41 in the fourth quarter, compared to $0.77 in the year-ago quarter. The current stock performance of Invivyd shows a 52-week-high of $4.89 and a 52-week-low of $1.03. Moreover, at the end of the last trading period, the closing price was at $1.10.

    HC Wainwright & Co. initiated coverage on Kineta Inc (NASDAQ:KA) with a Buy rating. The price target for Kineta is set to $8.00. NoneAt the moment, the stock has a 52-week-high of $9.00 and a 52-week-low of $1.00. Kineta closed at $3.97 at the end of the last trading period.

    With a Buy rating, Goldman Sachs initiated coverage on TD Synnex Corp (NYSE:SNX). The price target seems to have been set at $101.00 for TD Synnex. TD Synnex earned $2.93 in the first quarter, compared to $3.03 in the year-ago quarter. The stock has a 52-week-high of $111.57 and a 52-week-low of $79.14. At the end of the last trading period, TD Synnex closed at $89.04.

    See all analyst ratings initiations.

    Get the next $ALHC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ALHC
    $ARBK
    $ARCB
    $AVB

    CompanyDatePrice TargetRatingAnalyst
    Doximity Inc.
    $DOCS
    2/9/2026$34.00Hold → Buy
    Canaccord Genuity
    Biogen Inc.
    $BIIB
    2/9/2026$194.00 → $228.00Buy
    H.C. Wainwright
    Doximity Inc.
    $DOCS
    2/6/2026$40.00Underweight → Neutral
    Analyst
    Stoke Therapeutics Inc.
    $STOK
    2/5/2026$60.00Buy
    Guggenheim
    Allbirds Inc.
    $BIRD
    2/4/2026Buy → Hold
    Maxim Group
    Exxon Mobil Corporation
    $XOM
    2/3/2026$125.00Neutral → Underperform
    BNP Paribas Exane
    Exxon Mobil Corporation
    $XOM
    2/3/2026$135.00 → $145.00Buy
    TD Cowen
    Otis Worldwide Corporation
    $OTIS
    1/30/2026$98.00Overweight → Neutral
    Analyst
    More analyst ratings

    $ALHC
    $ARBK
    $ARCB
    $AVB
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Roivant Sciences Ltd. bought $349,999,986 worth of shares (16,666,666 units at $21.00), increasing direct ownership by 17% to 113,317,007 units (SEC Form 4)

    4 - Immunovant, Inc. (0001764013) (Issuer)

    12/12/25 5:17:21 PM ET
    $IMVT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Mclaughlin Kevin F bought $125,000 worth of shares (50,000 units at $2.50) (SEC Form 4)

    4 - Invivyd, Inc. (0001832038) (Issuer)

    11/20/25 4:22:07 PM ET
    $IVVD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Fox Jonathan C bought $199,403 worth of shares (10,700 units at $18.64), increasing direct ownership by 82% to 23,702 units (SEC Form 4)

    4 - Edgewise Therapeutics, Inc. (0001710072) (Issuer)

    11/13/25 6:04:59 PM ET
    $EWTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALHC
    $ARBK
    $ARCB
    $AVB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Doximity upgraded by Canaccord Genuity with a new price target

    Canaccord Genuity upgraded Doximity from Hold to Buy and set a new price target of $34.00

    2/9/26 6:58:22 AM ET
    $DOCS
    EDP Services
    Technology

    H.C. Wainwright reiterated coverage on Biogen with a new price target

    H.C. Wainwright reiterated coverage of Biogen with a rating of Buy and set a new price target of $228.00 from $194.00 previously

    2/9/26 6:43:59 AM ET
    $BIIB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Doximity upgraded by Analyst with a new price target

    Analyst upgraded Doximity from Underweight to Neutral and set a new price target of $40.00

    2/6/26 8:05:27 AM ET
    $DOCS
    EDP Services
    Technology

    $ALHC
    $ARBK
    $ARCB
    $AVB
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for VUMERITY issued to BIOGEN INC

    Submission status for BIOGEN INC's drug VUMERITY (ORIG-1) with active ingredient DIROXIMEL FUMARATE has changed to 'Approval' on 09/12/2024. Application Category: NDA, Application Number: 761347, Application Classification: Type 3 - New Dosage Form

    9/16/24 6:52:10 AM ET
    $BIIB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    FDA Approval for VUMERITY issued to BIOGEN INC

    Submission status for BIOGEN INC's drug VUMERITY (SUPPL-17) with active ingredient DIROXIMEL FUMARATE has changed to 'Approval' on 09/11/2024. Application Category: NDA, Application Number: 211855, Application Classification: Manufacturing (CMC)

    9/16/24 6:24:32 AM ET
    $BIIB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    July 30, 2024 - FDA Roundup: July 30, 2024

    For Immediate Release: July 30, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA is announcing the fiscal year (FY) 2025 user fee rates for importers approved to participate in the Voluntary Qualified Importer Program (VQIP) and accreditation and certification bodies interested in participating in the Accredited Third-Party C

    7/30/24 3:38:18 PM ET
    $GH
    Medical Specialities
    Health Care

    $ALHC
    $ARBK
    $ARCB
    $AVB
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Treace Medical Concepts Inc.

    SCHEDULE 13G/A - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Subject)

    2/12/26 5:57:53 PM ET
    $TMCI
    Medical/Dental Instruments
    Health Care

    SEC Form 144 filed by Zillow Group Inc.

    144 - ZILLOW GROUP, INC. (0001617640) (Subject)

    2/12/26 4:09:42 PM ET
    $ZG
    Real Estate

    SEC Form 424B5 filed by Coherus Oncology Inc.

    424B5 - Coherus Oncology, Inc. (0001512762) (Filer)

    2/12/26 4:08:22 PM ET
    $CHRS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ALHC
    $ARBK
    $ARCB
    $AVB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Innovation Officer Scanlan Sean F. exercised 16,875 shares at a strike of $1.05, increasing direct ownership by 2% to 706,474 units (SEC Form 4)

    4 - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Issuer)

    2/11/26 9:00:03 PM ET
    $TMCI
    Medical/Dental Instruments
    Health Care

    Co -Exec. Chairman & President Frink Lloyd D exercised 27,774 units of Class C Capital Stock at a strike of $22.41 and sold $1,439,954 worth of Class C Capital Stock (27,774 units at $51.85) (SEC Form 4)

    4 - ZILLOW GROUP, INC. (0001617640) (Issuer)

    2/11/26 6:41:28 PM ET
    $ZG
    Real Estate

    Chief Human Resources Officer Wagner Andreas P. sold $455,212 worth of shares (22,238 units at $20.47), decreasing direct ownership by 12% to 169,805 units (SEC Form 4)

    4 - Alignment Healthcare, Inc. (0001832466) (Issuer)

    2/10/26 9:51:27 PM ET
    $ALHC
    Medical Specialities
    Health Care

    $ALHC
    $ARBK
    $ARCB
    $AVB
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Treace Updates Date of Fourth Quarter and Full-Year 2025 Financial Results Release to February 27, 2026

    PONTE VEDRA, Fla., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NASDAQ:TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities, today announced that it will release financial results for the fourth quarter and full year of 2025 before the open of trading on Friday, February 27, 2026. Company management will host a conference call to discuss financial results beginning at 8:00 am ET. Investors interested in listening to the conference call may do so by registering. Once registered, participants will receive dial-in numbers and a unique pin to join the call and ask qu

    2/12/26 5:13:32 PM ET
    $TMCI
    Medical/Dental Instruments
    Health Care

    Logitech to Participate in Upcoming Investor Conferences

    Logitech International (SIX: LOGN) (NASDAQ:LOGI) today announced that Company leaders plan to participate at the following investor conferences: Goldman Sachs European Technology Conference in London, UK on Wednesday, February 25, 2026, at 12:30 p.m. GMT. Bernstein's 4th Annual Tech Sector (TMT) Conference in Palo Alto, California on Wednesday, February 25, 2026, at 9:00 a.m. PST. Morgan Stanley Technology, Media & Telecom Conference in San Francisco, California on Wednesday, March 4, 2026, at 1:50 p.m. PST. Links to the webcasts will be available on the Logitech corporate website at http://ir.logitech.com. About Logitech Logitech designs software-enabled hardware solutions

    2/12/26 4:05:00 PM ET
    $LOGI
    Computer peripheral equipment
    Technology

    Coherus Oncology, Inc. Announces Proposed Public Offering of Common Stock

    REDWOOD CITY, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. ("Coherus" or the "Company") (NASDAQ:CHRS), today announced a proposed underwritten public offering of its common stock (the "Offering"). In addition, Coherus intends to grant the underwriters a 30-day option to purchase additional shares of its common stock in an amount up to 15% of the shares offered in the Offering, at the public offering price per share less underwriting discounts and commissions. All of the shares in the Offering are being offered by Coherus. Coherus intends to use the net proceeds from the proposed Offering to support the ongoing commercialization of LOQTORZI® (toripalimab-tpzi), to conti

    2/12/26 4:05:00 PM ET
    $CHRS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ALHC
    $ARBK
    $ARCB
    $AVB
    Insider purchases explained

    Analytical look into recent insider purchases

    View All

    Insider Analysis: Purchase at Exxon Mobil Corporation on Jun 20

    Director Dreyfus Maria S. bought $2,000,386 worth of shares (18,310 units at $109.25), increasing direct ownership by 105% to 35,757 units (SEC Form 4) on June 20, 2024. This substantial insider purchase is a significant development for Exxon Mobil Corporation. As we delve into the recent insider activity at Exxon Mobil, we notice a few interesting patterns. Prior to Dreyfus Maria S.'s purchase, we observed that on January 4, 2024, Ubben Jeffrey W. granted 2,500 shares, which could signal confidence in the company. On the same day, Powell Dina H. claimed no ownership of stock but was granted 8,000 shares, indicating a new ownership stake. These events suggest a mix of adjustments in holding

    6/20/24 1:39:11 PM ET
    $XOM
    Integrated oil Companies
    Energy

    $ALHC
    $ARBK
    $ARCB
    $AVB
    Leadership Updates

    Live Leadership Updates

    View All

    Valley Bank Strengthens Leadership Team to Accelerate Partner Banking, Digital Innovation, and Customer Care

    New senior appointments advance Valley's growth strategy across fintech partnerships, digital channels, and relationship-driven banking Valley National Bank, a subsidiary of Valley National Bancorp (NASDAQ:VLY), today announced the appointment of three senior leaders: Rodrigo Suarez as Head of Partner Banking, Stephen Schroth as the Head of Digital & Assisted Channels, and Ed Montesdeoca to lead Customer Care & Strategy. Together, these appointments underscore Valley's continued investment in innovation, customer experience and digital transformation. Partner Banking is a key component of Valley's long-term growth strategy, enabling the Bank to collaborate with fintechs, technology plat

    2/11/26 8:00:00 AM ET
    $VLY
    Major Banks
    Finance

    Teradata Advances Board Refreshment Program

    Expects to Appoint Melissa Fisher to the Board Enters into Cooperation Agreement with Lynrock Lake SAN DIEGO, Feb. 10, 2026 /PRNewswire/ -- Teradata Corporation (NYSE:TDC) ("Teradata" or the "Company") today announced the following changes to its Board of Directors (the "Board") as part of the Board's ongoing refreshment program and in connection with a cooperation agreement (the "Agreement") with Lynrock Lake LP and certain related parties ("Lynrock Lake"): The Board expects to appoint Melissa Fisher to the Board as a Class I director no later than March 1, 2026, following the completion of customary onboarding procedures. Ms. Fisher is expected to be nominated for election at the Company'

    2/10/26 4:23:00 PM ET
    $TDC
    Computer Software: Prepackaged Software
    Technology

    ImageneBio Appoints Immunology Drug Development Veteran Dr. Ben Porter-Brown as Chief Medical Officer

    Brings 20+ years of clinical development experience in autoimmune and inflammatory diseases, including OX40/OX40L program leadership Will build and lead Imagene's clinical organization and drive completion of the Phase 2b ADAPTIVE trial in atopic dermatitis Will expand Phase 2b trial footprint with planned international sites including in the UK and Europe SAN DIEGO, Feb. 10, 2026 (GLOBE NEWSWIRE) -- ImageneBio, Inc. (NASDAQ:IMA, "Imagene, " or the "Company")), today announced the appointment of Dr. Ben Porter-Brown, a seasoned autoimmune and inflammatory drug developer with experience in the OX40 receptor-ligand (OX40-OX40L) inhibition field, as its Chief Medical Officer. He will be fo

    2/10/26 7:00:00 AM ET
    $IMA
    $MLTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    $ALHC
    $ARBK
    $ARCB
    $AVB
    Financials

    Live finance-specific insights

    View All

    Treace Updates Date of Fourth Quarter and Full-Year 2025 Financial Results Release to February 27, 2026

    PONTE VEDRA, Fla., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NASDAQ:TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities, today announced that it will release financial results for the fourth quarter and full year of 2025 before the open of trading on Friday, February 27, 2026. Company management will host a conference call to discuss financial results beginning at 8:00 am ET. Investors interested in listening to the conference call may do so by registering. Once registered, participants will receive dial-in numbers and a unique pin to join the call and ask qu

    2/12/26 5:13:32 PM ET
    $TMCI
    Medical/Dental Instruments
    Health Care

    Copart, Inc. to Release Second Quarter Fiscal 2026 Results

    Copart, Inc. (NASDAQ:CPRT) announced today that it will release earnings for the second quarter of fiscal 2026 after 4:00 p.m. Eastern Time (3:00 p.m. Central) on Thursday, February 19, 2026. On Thursday, February 19, 2026, at 5:30 p.m. Eastern Time (4:30 p.m. Central), Copart will conduct a conference call to discuss the results for the quarter. The call will be webcast live and available for access by clicking "Listen Here" at www.copart.com/investorrelations. A replay of the call will be available through May 2026 at www.copart.com/investorrelations. About Copart Founded in 1982, Copart is a global leader in online vehicle auctions. Copart's innovative technology and online auction

    2/11/26 10:05:00 PM ET
    $CPRT
    Retail-Auto Dealers and Gas Stations
    Consumer Discretionary

    Teradata Reports Fourth Quarter and Full-Year 2025 Financial Results

    Fourth quarter Total ARR of $1.522 billion, an increase of 3% as reported and 1% in constant currency from the prior year period(1)Fourth quarter Recurring Revenue of $367 million, up 5% as reported and 3% in constant currency(1)Fourth quarter GAAP diluted EPS of $0.38 and non-GAAP diluted EPS of $0.74(2)Full-Year 2025 Cash Flow from Operations of $305 million and Free Cash Flow of $285 million(3)SAN DIEGO, Feb. 10, 2026 /PRNewswire/ -- Teradata (NYSE: TDC) today announced its fourth quarter and full-year 2025 financial results. "Teradata delivered another set of strong results in the 4th quarter, as we again exceeded expectations for Total Revenue, Recurring Revenue and Free Cash Flow," sa

    2/10/26 4:05:00 PM ET
    $TDC
    Computer Software: Prepackaged Software
    Technology

    $ALHC
    $ARBK
    $ARCB
    $AVB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Copart Inc. (DE)

    SC 13G/A - COPART INC (0000900075) (Subject)

    12/16/24 7:28:03 PM ET
    $CPRT
    Retail-Auto Dealers and Gas Stations
    Consumer Discretionary

    Amendment: SEC Form SC 13D/A filed by Invivyd Inc.

    SC 13D/A - Invivyd, Inc. (0001832038) (Subject)

    12/12/24 4:39:09 PM ET
    $IVVD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Stoke Therapeutics Inc.

    SC 13G/A - Stoke Therapeutics, Inc. (0001623526) (Subject)

    11/14/24 9:00:58 PM ET
    $STOK
    Biotechnology: Pharmaceutical Preparations
    Health Care